Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Neurodegenerative start-up Denali Therapeutics nets $267.4mm in IPO

Executive Summary

Denali Therapeutics Inc. (neurodegenerative disease drug development) netted $267.4mm in an initial public offering of 15.9mm shares (including the overallotment) at $18, the mid-point of its anticipated range. The company had originally planned to sell 8.33mm shares.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies